MIR5093

Across TCGA pan-cancer cohorts, MIR5093 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MIR5093’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR5093 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR5093 is over-expressed in tumor, although a few such as PRAD show the opposite, repressed pattern.

BRCA, LUSC, and PRAD are the cancer types where MIR5093 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MIR5093 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	II,III,IV	+0.241	.020	4	view →
LUSC	All	II,III,IV	+0.225	.007	3	view →
PRAD	All	All	−0.105	.019	2	view →
STAD	All	All	+0.098	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MIR5093–BRCA

Open the BRCA breakdown →